文献速递浆细胞疾病造血干细胞移植与细胞治疗

帕博利珠单抗联合泊马度胺和地塞米松治疗复发难治多发性骨髓瘤:KEYNOTE-183随机开放标签3期试验

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2019-07-18

KEYNOTE-183是一项在11国97中心开展的随机开放标签3期试验,评估帕博利珠单抗联合泊马度胺和地塞米松对比泊马度胺和地塞米松治疗复发难治多发性骨髓瘤。因FDA认为三联组合风险大于获益而中止研究,非计划中期分析显示联合组无进展生存期和总生存期均未改善,严重不良事件和治疗相关死亡更多。

要点

  • 联合组严重不良事件63% vs 对照组46%,治疗相关死亡4例 vs 0例。

核心结论

  • 非计划中期分析显示,帕博利珠单抗联合泊马度胺和地塞米松在复发难治多发性骨髓瘤患者中获益风险比不利。

研究设计与样本

  • 随机、开放标签、3期试验,在11国97个中心开展,共随机分配249例患者。
  • 患者按1:1随机接受帕博利珠单抗联合泊马度胺和地塞米松(n=125)或泊马度胺和地塞米松(n=124)。
  • 双主要终点为无进展生存期和总生存期;疗效分析纳入所有随机患者,安全性分析纳入至少接受一剂研究治疗的患者。

主要发现

  • 严重不良事件联合组75/120例(63%) vs 对照组56/121例(46%)。
  • 治疗相关死亡联合组4/120例(3%)(原因不明、中性粒细胞减少性脓毒症、心肌炎和Stevens-Johnson综合征各1例),对照组0例;其中心肌炎和Stevens-Johnson综合征被认为与帕博利珠单抗相关。

临床怎么用

  • 基于非计划、FDA要求的中期分析,帕博利珠单抗联合泊马度胺和地塞米松的获益风险比在复发难治多发性骨髓瘤患者中不利。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or without pembrolizumab in patients with relapsed or refractory multiple myeloma. Here, we present the findings of an unplanned, ad-hoc interim analysis at the request of the US Food and Drug Administration (FDA). METHODS: KEYNOTE-183 was a randomised, open-label, phase 3 trial done at 97 medical centres across 11 countries (Australia, Canada, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Spain, and USA). Patients aged at least 18 years with multiple myeloma, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, previously treated with at least two lines of therapy (excluding pomalidomide) and refractory to the last line were randomly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide and dexamethasone group via an interactive voice response or integrated web response system. Patients received oral pomalidomide 4 mg daily on days 1-21 and oral low-dose dexamethasone 40 mg on days 1, 8, 15, and 22 in 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The dual primary endpoints were progression-free survival and overall survival. Efficacy was assessed in all randomly assigned patients and safety was assessed in patients who received at least one dose of study treatment. The trial is registered at ClinicalTrials.gov, number NCT02576977, and it is closed for accrual. FINDINGS: Between Jan 18, 2016, and June 7, 2017, 249 patients were randomly assigned to either the pembrolizumab plus pomalidomide and dexamethasone group (n=125) or the pomalidomide and dexamethasone group (n=124). On July 3, 2017, the FDA established that risks associated with the triple combination outweighed benefits and halted the study. Median follow-up was 8·1 months (IQR 4·5-10·9). Median progression-free survival was 5·6 months (95% CI 3·7-7·5) in the pembrolizumab plus pomalidomide and dexamethasone group versus 8·4 months (5·9-not reached) in the pomalidomide and dexamethasone group; progression-free survival estimates at 6 months were 48% (95% CI 37-58) versus 60% (49-69) at 6 months (hazard ratio [HR] 1·53; 95% CI 1·05-2·22; p=0·98). Median overall survival was not reached (95% CI 12·9-not reached) versus 15·2 months (12·7-not reached; HR 1·61; 95% CI 0·91-2·85; p=0·95); overall survival estimates at 6 months were 82% (95% CI 74-88) versus 90% (82-95). Serious adverse events occurred in 75 (63%) of 120 patients in the pembrolizumab plus pomalidomide and dexamethasone group versus 56 (46%) of 121 patients in the pomalidomide and dexamethasone group. Four (3%) treatment-related deaths occurred in the pembrolizumab plus pomalidomide and dexamethasone group (one each of unknown cause, neutropenic sepsis, myocarditis, and Stevens-Johnson syndrome); myocarditis and Stevens-Johnson syndrome were considered related to pembrolizumab. No treatment-related deaths were reported in the pomalidomide and dexamethasone group. INTERPRETATION: The results from this unplanned, FDA-requested, interim analysis showed that the benefit-risk profile of pembrolizumab plus pomalidomide and dexamethasone is unfavourable for patients with relapsed or refractory multiple myeloma. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA).

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Mateos MV, Blacklock H, Schjesvold F, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019. PMID: 31327687. doi:10.1016/S2352-3026(19)30110-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。